Total Payments
$162,909
2024 Payments
$99.14
Companies
14
Transactions
265
Medicare Patients
8,940
Medicare Billing
$1.0M
Payment Breakdown by Category
Consulting$160,577 (98.6%)
Travel$1,171 (0.7%)
Food & Beverage$1,148 (0.7%)
Education$13.89 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $160,577 | 223 | 98.6% |
| Travel and Lodging | $1,171 | 9 | 0.7% |
| Food and Beverage | $1,148 | 32 | 0.7% |
| Education | $13.89 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $161,748 | 232 | $0 (2023) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $637.16 | 12 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $118.14 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $66.32 | 4 | $0 (2022) |
| Siemens Medical Solutions USA, Inc. | $64.88 | 1 | $0 (2017) |
| Boston Scientific Corporation | $45.54 | 2 | $0 (2024) |
| iRhythm Technologies, Inc. | $44.07 | 2 | $0 (2024) |
| GENZYME CORPORATION | $41.65 | 2 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $39.27 | 3 | $0 (2022) |
| Amgen Inc. | $30.57 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $99.14 | 5 | Boston Scientific Corporation ($45.54) |
| 2023 | $4,314 | 8 | NOVARTIS PHARMACEUTICALS CORPORATION ($4,271) |
| 2022 | $16,979 | 39 | Novartis Pharmaceuticals Corporation ($16,775) |
| 2021 | $47,697 | 86 | NOVARTIS PHARMACEUTICALS CORPORATION ($47,334) |
| 2020 | $10,108 | 22 | NOVARTIS PHARMACEUTICALS CORPORATION ($9,924) |
| 2019 | $25,096 | 34 | Novartis Pharmaceuticals Corporation ($24,894) |
| 2018 | $45,800 | 48 | Novartis Pharmaceuticals Corporation ($45,800) |
| 2017 | $12,815 | 23 | Novartis Pharmaceuticals Corporation ($12,750) |
All Payment Transactions
265 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $9.53 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/28/2024 | iRhythm Technologies, Inc. | ZIO XT Patch (Device), Zio monitor | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/24/2024 | Boston Scientific Corporation | SYNERGY (Device) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: SYNERGY_IC | ||||||
| 05/22/2024 | Boston Scientific Corporation | Emerge Push (Device) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Emerge_IC | ||||||
| 02/28/2024 | iRhythm Technologies, Inc. | Zio monitor (Device), ZIO XT Patch | Food and Beverage | In-kind items and services | $27.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/10/2023 | Novo Nordisk Inc | Saxenda (Drug), Wegovy | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Obesity | ||||||
| 03/23/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Immunology | ||||||
| 03/19/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Neurology | ||||||
| 03/19/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Travel and Lodging | In-kind items and services | $13.76 | General |
| Category: Neurology | ||||||
| 03/12/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Neurology | ||||||
| 03/12/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Travel and Lodging | In-kind items and services | $56.99 | General |
| Category: Neurology | ||||||
| 02/18/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Neurology | ||||||
| 01/21/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Neurology | ||||||
| 11/07/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Cardiology | ||||||
| 10/13/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/13/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $12.50 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $121.88 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Immunology | ||||||
| 10/04/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Education | In-kind items and services | $13.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/11/2022 | Biosense Webster, Inc. | CARTO 3 (Device) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Cardiology | ||||||
| 07/31/2022 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2022 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2022 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $166.88 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 3,333 | 4,339 | $2.8M | $373,684 |
| 2022 | 32 | 2,650 | 3,198 | $2.3M | $306,738 |
| 2021 | 26 | 1,707 | 2,025 | $1.3M | $194,979 |
| 2020 | 23 | 1,250 | 1,555 | $863,512 | $144,936 |
Total Patients
8,940
Total Services
11,117
Medicare Billing
$1.0M
Procedure Codes
115
All Medicare Procedures & Services
115 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 376 | 615 | $590,400 | $91,798 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 442 | 651 | $558,558 | $65,342 | 11.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 357 | 372 | $513,444 | $65,040 | 12.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 98 | 330 | $224,400 | $33,025 | 14.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 182 | 182 | $247,520 | $32,890 | 13.3% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 63 | 63 | $84,826 | $13,350 | 15.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 67 | 74 | $97,680 | $10,866 | 11.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $84,630 | $9,077 | 10.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 120 | 265 | $41,709 | $7,281 | 17.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 116 | 124 | $43,524 | $6,875 | 15.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 427 | 466 | $51,726 | $5,702 | 11.0% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Facility | 2023 | 56 | 57 | $31,920 | $5,397 | 16.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 69 | 70 | $38,290 | $4,340 | 11.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 22 | $39,600 | $3,950 | 10.0% |
| 99422 | Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | Office | 2023 | 74 | 100 | $14,550 | $2,453 | 16.9% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 92 | 99 | $12,383 | $2,165 | 17.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 27 | 27 | $8,019 | $1,942 | 24.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 108 | 110 | $17,328 | $1,915 | 11.0% |
| 99423 | Online digital evaluation and management service for an established patient for up to 7 days, total time 21 or more minutes | Office | 2023 | 40 | 44 | $10,060 | $1,732 | 17.2% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Office | 2023 | 104 | 132 | $9,258 | $1,577 | 17.0% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 109 | 111 | $8,261 | $1,272 | 15.4% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 91 | 98 | $7,203 | $1,107 | 15.4% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 54 | 58 | $6,323 | $1,088 | 17.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 28 | 28 | $3,780 | $954.56 | 25.3% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 12 | 24 | $7,288 | $803.63 | 11.0% |
About Dr. Peyman Nejatbakhsh Azadani, M.D
Dr. Peyman Nejatbakhsh Azadani, M.D is a Cardiovascular Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2011. The National Provider Identifier (NPI) number assigned to this provider is 1215220074.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peyman Nejatbakhsh Azadani, M.D has received a total of $162,909 in payments from pharmaceutical and medical device companies, with $99.14 received in 2024. These payments were reported across 265 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($160,577).
As a Medicare-enrolled provider, Nejatbakhsh Azadani has provided services to 8,940 Medicare beneficiaries, totaling 11,117 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 115 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Los Angeles, CA
- Active Since 05/25/2011
- Last Updated 08/01/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215220074
Products in Payments
- GILENYA (Drug) $141,812
- MAYZENT (Drug) $19,936
- LifeVest (Device) $637.16
- JARDIANCE (Drug) $118.14
- Non-Product Specific (Device) $64.88
- DUPIXENT (Biological) $41.65
- ELIQUIS (Drug) $39.27
- FARXIGA (Drug) $35.65
- BRILINTA (Drug) $30.67
- Repatha (Biological) $30.57
- Zio monitor (Device) $27.71
- Emerge Push (Device) $23.22
- CARTO 3 (Device) $23.16
- SYNERGY (Device) $22.32
- Saxenda (Drug) $20.31
- ZIO XT Patch (Device) $16.36
- ANGIO-SEAL (Device) $15.90
- Reveal LINQ (Device) $14.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Los Angeles
Dr. Leslie Saxon, M.d, M.D
Cardiovascular Disease — Payments: $1.6M
Cardiovascular Disease $1.6M
Dr. Cathleen Bairey Merz, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Ramin Ebrahimi, Md, MD
Cardiovascular Disease — Payments: $879,009
Cardiovascular Disease $879,009
Karol Watson, Md, MD
Cardiovascular Disease — Payments: $707,428
Cardiovascular Disease $707,428
Alexander Ford, Md, MD
Cardiovascular Disease — Payments: $563,203
Cardiovascular Disease $563,203
Rahul Doshi, M.d, M.D
Cardiovascular Disease — Payments: $479,484
Cardiovascular Disease $479,484